Pyxis Oncology founded by Longwood Fund with financing led by Bayer
Pyxis Oncology launched with a focus on developing a new family of antibody-based immunotherapies derived from novel insights into the biology of the tumor microenvironment. Bayer led the $22 million Series A financing and was joined by additional institutional and strategic investors. July 17, 2019